A csontáttétképzodés molekuláris alapjai és célzott terápiája

Translated title of the contribution: Molecular basis of bone metastasis formation and its targeted therapy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF receptor family member RANK and its ligand RANKL. The feasibility of using this system to control bone resorption or cancer-induced skeletal events was proven clinically in trials using an anti-RANKL antibody. The clinical success of anti-RANKL antibody therapy provide further evidence that only precise identification of molecular pathways operational in cancers can lead to discovery of more effective (targeted) therapies.

Original languageHungarian
Pages (from-to)59-64
Number of pages6
JournalMagyar Onkologia
Volume54
Issue number1
DOIs
Publication statusPublished - Mar 1 2010

Fingerprint

Osteogenesis
Neoplasm Metastasis
Osteoclasts
Bone Resorption
Therapeutics
Anti-Idiotypic Antibodies
RANK Ligand
Bone and Bones
Bone Neoplasms
Neoplasms
Organ Specificity
Bone Matrix
Tumor Necrosis Factor Receptors
Diphosphonates
Plastics

ASJC Scopus subject areas

  • Oncology

Cite this

A csontáttétképzodés molekuláris alapjai és célzott terápiája. / Tímár, J.

In: Magyar Onkologia, Vol. 54, No. 1, 01.03.2010, p. 59-64.

Research output: Contribution to journalArticle

@article{c5e8a892866c49e496043e043d32c528,
title = "A csont{\'a}tt{\'e}tk{\'e}pzod{\'e}s molekul{\'a}ris alapjai {\'e}s c{\'e}lzott ter{\'a}pi{\'a}ja",
abstract = "Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF receptor family member RANK and its ligand RANKL. The feasibility of using this system to control bone resorption or cancer-induced skeletal events was proven clinically in trials using an anti-RANKL antibody. The clinical success of anti-RANKL antibody therapy provide further evidence that only precise identification of molecular pathways operational in cancers can lead to discovery of more effective (targeted) therapies.",
keywords = "Bone metastasis, Molecular mechanism, Targeted therapy",
author = "J. T{\'i}m{\'a}r",
year = "2010",
month = "3",
day = "1",
doi = "10.1556/MOnkol.54.2010.1.8",
language = "Hungarian",
volume = "54",
pages = "59--64",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A csontáttétképzodés molekuláris alapjai és célzott terápiája

AU - Tímár, J.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF receptor family member RANK and its ligand RANKL. The feasibility of using this system to control bone resorption or cancer-induced skeletal events was proven clinically in trials using an anti-RANKL antibody. The clinical success of anti-RANKL antibody therapy provide further evidence that only precise identification of molecular pathways operational in cancers can lead to discovery of more effective (targeted) therapies.

AB - Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis of bone metastasis formation is the activation of osteoclasts and the resulting bone resorption, initiating a vicious circle by activating the initiator cancer cell. The discovery of osteoclast-bone matrix interaction inhibitor bisphosphonates revolutionized the therapy of bone metastasis. Clarifying the molecular pathways involved in bone metastasis formation identified osteoclast differentiation as another feasible target. This process is under control of the TNF receptor family member RANK and its ligand RANKL. The feasibility of using this system to control bone resorption or cancer-induced skeletal events was proven clinically in trials using an anti-RANKL antibody. The clinical success of anti-RANKL antibody therapy provide further evidence that only precise identification of molecular pathways operational in cancers can lead to discovery of more effective (targeted) therapies.

KW - Bone metastasis

KW - Molecular mechanism

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77950249104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950249104&partnerID=8YFLogxK

U2 - 10.1556/MOnkol.54.2010.1.8

DO - 10.1556/MOnkol.54.2010.1.8

M3 - Article

C2 - 20350869

AN - SCOPUS:77950249104

VL - 54

SP - 59

EP - 64

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -